Bdellovibrio bacteriovorus protects Caenorhabditis elegans from bacterial pathogens by Emmert, Elizabeth A.B. et al.
BDELLOVIBRIO 
BACTERIOVORUS 
PROTECTS 
CAENORHABDITIS 
ELEGANS FROM 
BACTERIAL PATHOGENS
ELIZABETH A. B. EMMERT, ZACHARY M. HAUPT, 
KATHERINE M. PFLAUM, JENNIFER L. LASBURY, JUSTIN P. 
MCGRATH, ALLISON E. COLLINS, AND CHRISTOPHER H. 
BRIAND 
DEPARTMENT OF BIOLOGICAL SCIENCES, SALISBURY 
UNIVERSITY, SALISBURY, MARYLAND
Copyright 2014, Fine Focus all rights reserved
MANUSCRIPT RECEIVED 29 APRIL, 2014; ACCEPTED 14 JUNE, 2014
Bdellovibrio bacteriovorus is a naturally predatory 
bacterium that multiplies inside Gram negative prey 
bacteria.  There is much interest in using Bdellovibrio 
as a living antibiotic to control infections by Gram 
negative pathogens.  In recent years Caenorhabditis 
elegans has proven to be an attractive animal model 
of bacterial pathogenesis for a range of pathogens.  
We have used the C. elegans animal pathogenesis 
model to examine the ability of B. bacteriovorus to 
protect nematodes from four bacterial pathogens.  In 
all cases, nematodes treated with B. bacteriovorus 
and the pathogen survived at a significantly higher 
level than nematodes treated with the pathogen alone.  
Treatment with B. bacteriovorus alone was nontoxic 
to the worms.  We monitored the persistence of E. coli 
K-12 and E. coli OP50 in both B. bacteriovorus treated 
nematodes and control nematodes.  E. coli K-12 levels 
were significantly lower in B. bacteriovorus treated 
nematodes than in control nematodes one day after 
Bdellovibrio exposure and E. coli K-12 was eliminated 
from the worm gut two days faster in B. bacteriovorus 
treated nematodes.  E. coli OP50 also demonstrated 
significantly lower levels in B. bacteriovorus treated 
nematodes and faster elimination from the worm gut.  
The successful use of B. bacteriovorus as a therapeutic 
agent in C. elegans indicates that it may be useful as a 
living antibiotic in other animal systems.
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INTRODUCTION
Bdellovibrio bacteria are intriguing because 
they naturally reproduce inside other Gram 
negative bacteria.  The Bdellovibrio life cycle 
involves attachment to and penetration of prey 
cells, elongation inside the prey periplasm using 
prey components for growth, fragmentation 
into multiple cells, and finally, lysis of the 
prey cell (1).   Because Bdellovibrio lyses prey 
as it multiplies, and because it cannot infect 
eukaryotic cells, there is growing interest in 
using Bdellovibrio as a “living antibiotic” (2).  
Numerous researchers have demonstrated in 
vitro killing of pathogens by Bdellovibrio, (3, 4, 
5, 6) supporting the idea of using Bdellovibrio 
to control infections.  Additionally, Bdellovibrio 
has been shown to attack prey within bacterial 
biofilms and reduce biofilm biomass (7, 8, 
9).  Two studies have put the living antibiotic 
concept into practice, demonstrating protection 
against Aeromonas hydrophila infection in fish 
and protection against Proteus penneri infection 
in shrimp through the use of Bdellovibrio 
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(10, 11).  Fish and shrimp mortality was 
significantly lower when the animals swam 
in water containing both the pathogen and 
Bdellovibrio as compared to animals in water 
containing only the pathogen.  However, it was 
not determined whether the mechanism of 
Bdellovibrio protection was simply a reduction 
of the pathogen level in the water, the killing 
of the pathogen within the animal, or a 
combination of the two.  Until recently, the 
use of Bdellovibrio as an in vivo treatment for 
infection has been an intriguing, but theoretical 
option.  In 2011 Atterbury et al. demonstrated 
Bdellovibrio could be used therapeutically 
to control Salmonella infection in chickens 
without negative effects on the birds (12).  This 
was the first study to demonstrate in vivo 
efficacy of Bdellovibrio as a treatment for 
bacterial infection.  Here we continue the use of 
Bdellovibrio as an in vivo therapeutic agent, but 
in the C. elegans bacterial pathogenesis model.
In 1999 Tan et al. first reported the use of 
the nematode C. elegans as an animal model 
for bacterial pathogenesis (13).  Since then 
numerous researchers have demonstrated that 
this system can be used for multiple bacterial 
pathogens including Pseudomonas aeruginosa, 
Salmonella enterica, Serratia marcescens, and 
Staphylococcus aureus (14, 15).  Genes identified 
in C. elegans as important in pathogenesis 
have been confirmed in mouse models of 
pathogenesis, validating the use of C. elegans as 
a pathogenesis model (16).  Using C. elegans as 
an animal model for pathogenesis is attractive 
for numerous reasons such as low cost, short 
generation time, complete genome sequence 
and ease of genetic manipulation (17).  When C. 
elegans are maintained in the laboratory they 
are grown on Petri plates containing lawns of 
nonpathogenic E. coli OP50 as their food source 
and the worms typically live two weeks (18).  
When grown on a pathogen instead of OP50, 
worm survival is greatly reduced (16).
Our lab has taken advantage of the well-
studied C. elegans bacterial pathogenesis 
model system to examine the use of 
Bdellovibrio to protect C. elegans from 
bacterial infection.  In this study, we first 
established an infection in the nematode and 
then examined the curative effect of a brief 
exposure to Bdellovibrio.  We show that 
worms treated with both Bdellovibrio and a 
pathogen live significantly longer than worms 
treated with the pathogen alone.  We also 
demonstrate that bacterial levels are lower and 
cleared faster in Bdellovibrio treated worms 
than control worms.  This work demonstrates 
that Bdellovibrio can be used as a therapeutic 
treatment for bacterial infections in a well-
defined animal model. 
MATERIALS AND METHODS
NEMATODE AND BACTERIAL 
STRAINS
Wild type C. elegans N2 worms were 
used in all nematode assays.  Worms and 
nonpathogenic E. coli OP50 were supplied 
by the Caenorhabditis Genetics Center 
(Minneapolis, MN).  Worms were grown on 
nematode growth medium (NGM) with E. 
coli OP50 as the food source (18).  Pathogens 
tested were E. coli K-12, Enterobacter 
aerogenes ATCC 13048, Pantoea agglomerans 
LS005, and Salmonella enterica serovar 
Typhimurium LT2 (19).  B. bacteriovorus 
HD100 was used for all biocontrol assays 
(20).  E. coli HB101 was used as the non-
pathogenic control in the biocontrol assays 
since our early work in this system used B. 
bacteriovorus 109J, which does not infect 
E. coli OP50, but does infect E. coli HB101.  
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However, all the experiments described here 
used B. bacteriovorus HD100, which does 
infect both E. coli OP50 and E. coli HB101.  B. 
bacteriovorus HD100 was cultured using E. 
coli K-12 as prey according to standard pro-
tocols (21).  B. bacteriovorus prey lysates were 
checked microscopically for active, motile B. 
bacteriovorus cells and an absence of prey 
cells.  Prey lysates contained approximately 
6 x 108 B. bacteriovorus cells per ml.  The 
persistence assays utilized kanamycin-resis-
tant E. coli K-12 derivative strain JW1863-1 
(22), supplied by the E. coli Genetic Stock 
Center (New Haven, CT) and ampicillin-re-
sistant E. coli OP50-GFP strain DB15, kindly 
supplied by J. Ewbank (Centre d’Immunolo-
gie de Marseille-Luminy, Marseille, France). 
PATHOGENICITY ASSAY
Bacteria were grown overnight in LB broth 
and 50 μl culture was spread on 60 mm di-
ameter NGM plates.  Plates were incubated for 
two days at 25°C to establish bacterial lawns.  
C. elegans were reared on NGM with lawns 
of E. coli OP50 as the food source.  One-day 
old adult worms were placed on NGM plates 
containing lawns of bacteria.  Worm survival 
was monitored daily for the next nine days.  
Worms were considered dead when they 
did not respond to gentle prodding with a 
platinum wire.  Surviving adult worms were 
transferred daily to fresh bacterial lawn plates 
to separate them from newly hatched juvenile 
worms.  Each trial measured the survival of 30 
worms per treatment. 
BIOCONTROL ASSAY
Bacteria were grown overnight in LB broth 
and 50 μl culture was spread on NGM plates.  
Plates were incubated for two days at 25°C 
to establish bacterial lawns.  C. elegans were 
reared on NGM with lawns of E. coli OP50 
as the food source.  One day old adult worms 
were placed on NGM plates containing lawns 
of a pathogen or nonpathogenic E. coli HB101.  
After exposing the worms to the pathogen 
or HB101 for 48 hours (32 hours for E. coli 
K-12), worms were washed three times in 
Ca/HEPES buffer (21) to remove external 
bacteria.  E. coli K-12 treated worms were 
exposed to E. coli for 32 hours instead of 48 
hours because a 48 hour exposure to E. coli 
K-12 was too toxic and killed the majority of 
the worms.  Washed worms were suspended 
in 1 ml of an active B. bacteriovorus prey 
lysate or 1ml of Ca/HEPES buffer for 
15 minutes.  A 15 minute exposure to B. 
bacteriovorus was chosen because this is the 
time required for B. bacteriovorus to attach to 
prey cells (2).  Then the worms were pelleted 
and placed on NGM plates containing lawns 
of the nonpathogenic E. coli HB101.  Worms 
were transferred to new E. coli HB101 plates 
daily and worm survival was monitored daily 
for the next seven days.  Each trial measured 
the survival of 40-50 worms per treatment.  
E. COLI PERSISTENCE IN C. 
ELEGANS
Nematodes were exposed to an antibiotic-
resistant strain of E. coli (32 hour exposure 
for kanamycin-resistant E. coli K-12 
derivative JW1863-1 or 48 hour exposure 
for ampicillin-resistant E. coli OP50-GFP 
strain DB15) followed by three washes in 
Ca/HEPES buffer.  The washed worms 
were suspended for 15 minutes in either 1 
ml of an active B. bacteriovorus prey lysate 
or 1 ml of Ca/HEPES buffer, then pelleted 
and placed on NGM plates with E. coli 
HB101 lawns.  Worms were transferred 
daily on to fresh E. coli HB101 plates as 
described above for the biocontrol assays.  
Numbers of internal bacteria persisting 
in the nematodes after B. bacteriovorus or 
buffer exposure were determined daily 
using the protocol of Garsin et al. (23) 
with the following modifications.  Briefly, 
5 worms were placed on a LB agar plate 
containing the appropriate antibiotic 
(50 μg/ml) and washed twice with 4 μl 
RESULTS
PATHOGENICITY ASSAY
We tested the pathogenicity of four species 
of bacteria, comparing them to the standard, 
nonpathogenic E. coli OP50 routinely used to 
maintain C. elegans.  All four species tested 
were pathogenic when compared to E. coli 
OP50, greatly reducing worm survival (Fig. 
1).  The pairwise comparisons examining 
worm survival between the four pathogens 
indicated that all four pathogens were similar 
in pathogenicity (p=0.9926).  We also tested E. 
coli HB101 and found it to be nonpathogenic.  
Worm survival on E. coli HB101 was not 
significantly different from worm survival on 
E. coli OP50 (p=0.5482).  Worms grown on all 
four pathogens survived significantly less than 
worms grown on E. coli OP50 (p<0.001) and 
worms grown on all four pathogens survived 
significantly less than worms grown on E. 
coli HB101 (p<0.001).  We proceeded to use E. 
coli HB101 as the C. elegans food source when 
monitoring worm survival in our biocontrol 
assays rather than E. coli OP50 since our early 
work in this system used B. bacteriovorus strain 
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Figure 1.  Survival 
curves for C. elegans 
exposed to E. coli 
OP50 (   ), E. coli 
HB101 (   ), E. coli 
K-12 (  ), E. aerogenes 
(   ), P. agglomerans  
(   ), and S. enterica 
(   ). Data are 
from one trial 
representative of two 
independent trials.
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M9 medium to remove surface bacteria.  
Washed worms were suspended in 20 μl 
M9 medium and ground with a pestle.  30 
μl of M9 medium was added to the worm 
solution to bring the total volume up to 50 
μl; the solution was diluted in Ca/HEPES 
buffer and plated on LB agar containing 
the appropriate antibiotic (50 μg/ml) for 
bacterial enumeration.  
STATISTICS
Kaplan-Meir survival analysis followed 
by pairwise logrank tests (24, 25, 26) was 
used to analyze C. elegans survival over 
time.  The Mann Whitney test was used to 
analyze E. coli persistence data.  Data analyses 
were performed using GraphPad Prism® 4 
(27).  The significance level for all statistical 
analyses was set at a = 0.05.
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Fig. 2.  Survival curves for C. elegans exposed to (a) E. coli K-12 (b) E. aerogenes (c) P. agglomerans 
and (d) S. enterica.  Worms were treated with nonpathogenic E. coli HB101 (   ), HB101 and 
Bdellovibrio (   ), pathogen (   ), or pathogen and Bdellovibrio (   ).  Worms were exposed to 
Bdellovibrio or control buffer on day one.  Data are from three independent trials for each pathogen.
  P values for pairwise comparisons in the biocontrol assay survival curves.. 
       Pathogen                  Comparison  
 HB101 
vs. 
HB101  + Bda
HB101  
vs.  
Pathogen 
HB101 
vs. 
Pathogen +  Bd
HB101 
+
 
Bd
 
vs.
Pathogen 
HB101 + Bd
vs. 
Pathogen +  Bd  
Pathogen 
vs. 
Pathogen +  Bd  
E. coli K-12 0.4958 <0.0001 0.0047 <0.0001 0.0412 <0.0001 
E. aerogenes 0.4402 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
0.7376 <0.0001 0.0207 <0.0001 0.0098 <0.0001 
S. enterica 0.7318 <0.0001 0.1901 <0.0001 0.3292 <0.0001 
 a
 Bd indicates 
P. agglomerans
Table 1
aBd indicates Bdellovibrio
 ir ise comparisons in the biocontrol assay sur ival curves.
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109J, which did not prey on E. coli OP50.   
BIOCONTROL ASSAY
To determine whether B. bacteriovorus 
could protect nematodes from bacterial 
pathogens, we established infections in the 
nematodes, briefly treated infected worms 
with B. bacteriovorus, placed worms on 
non-pathogenic E. coli HB101, and monitored 
worm survival for seven days.  For all 
four pathogens tested, worm survival was 
significantly improved when worms were 
treated with B. bacteriovorus as compared 
to the pathogen alone (Fig. 2).  For each 
pathogen, the pairwise comparison between 
worms treated with the pathogen alone 
and worms treated with both the pathogen 
and Bdellovibrio was highly significant 
(Table 1).  Worm survival was unaffected 
by B. bacteriovorus treatment when 
worms were grown on nonpathogenic 
E. coli HB101 (Table 1), demonstrating that 
B. bacteriovorus is nontoxic to worms.  
Bdellovibrio and pathogen treated worms 
had significantly longer survival than 
worms treated with the pathogen alone.  
However, for three of the four pathogens, 
Bdellovibrio treatment was unable to restore 
the same level of worm survival as with 
the nonpathogenic E. coli HB101 control, 
and there were still significant survival 
differences between control worms and 
pathogen plus Bdellovibrio treated worms.  
S. enterica infection was the only one 
completely rescued by Bdellovibrio with 
no significant difference in survival curves 
between control worms and S. enterica plus 
Bdellovibrio treated worms (Table 1).  
E. COLI PERSISTENCE IN C. 
ELEGANS
We also monitored the persistence of 
one of the four pathogens (a kanamycin-
resistant derivative of E. coli K-12) as well as 
ampicillin-resistant E. coli OP50 in both
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Fig. 3.  Persistence of antibiotic-resistant 
derivatives of (a) E. coli K-12 and (b) E. 
coli OP50 within C. elegans treated with 
Bdellovibrio (black bars) or control buffer 
(grey bars).  Worms were treated with 
Bdellovibrio or control buffer on day 
zero.  Values with the same letter for a 
single time are not significantly different 
(p≤0.05).  Asterisks indicate values with 
zero variance and thus these days were 
excluded from analysis.  Log transformed 
data are from four independent trials and 
error bars indicate standard error.
1 2 3 4 5
0
1
2
3
Time (days)
Lo
g 
cf
u 
pe
r 
5 
w
or
m
s
b
a
a
a
* *
Time (days)
Time (days)
A.
B.
Lo
g 
C
FU
 p
er
 5
 w
or
m
s
Lo
g 
C
FU
 p
er
 5
 w
or
m
s
DISCUSSION
While many have used C. elegans as 
a model for bacterial pathogenesis, we 
have extended that model to investigate 
control of four bacterial pathogens by 
Bdellovibrio.  The non-vertebrate C. 
elegans has many advantages as an animal 
model for Bdellovibrio infection control 
studies  including short life span, ease of 
manipulation, low cost, consumption of 
bacteria as food, and absence of ethical 
concerns.  Our work in C. elegans supports 
and extends earlier work using Bdellovibrio 
as a therapeutic agent to control bacterial 
infections in chickens (12).  Interestingly, 
the one log reduction in S. enterica by 
Bdellovibrio in chickens is similar to 
the reduction in E. coli K-12 levels we 
demonstrated in C. elegans (Fig. 3A).  In 
agreement with the chicken study, our work 
demonstrated improved animal health with 
a single, discrete dose of Bdellovibrio.  Using 
Bdellovibrio to control infection is often 
compared to bacteriophage therapy with 
Bdellovibrio having the advantage of a wider 
prey range than phage (2).  Indeed, similar to 
our results, one group has demonstrated the 
ability of phage to protect C. elegans from 
Salmonella infection (28) confirming the 
robustness of the C. elegans model.  
Our pathogenicity assay results demonstrate 
a clear difference in nematode survival 
between the four pathogens tested and 
the two non-pathogenic E. coli strains 
(Fig. 1).  This highly significant survival 
difference is also reflected in the biocontrol 
assay comparing the HB101 treated worms 
with the pathogen treated worms (Fig. 2).  
Although E. coli K-12 is typically considered 
to be nonpathogenic in animal models and 
our referring to E. coli K-12 as a pathogen 
may seem inaccurate, others have also 
demonstrated that E. coli K-12 is pathogenic 
in C. elegans (29).  E. coli OP50 is the strain 
typically used as a nonpathogenic food 
source for C. elegans; however we have 
demonstrated that E. coli strain HB101 is also 
nonpathogenic. Similar nematode survival 
curves between OP50 and HB101 have 
also been demonstrated by researchers 
examining the effect of bacterial nutrition 
on C. elegans lifespan (30).  Interestingly, 
when survival is examined beyond ten days, 
worms live longer on HB101 compared to 
survival on OP50 (30).
Although Bdellovibrio provided intermediate 
protection from most pathogens, the 
significant improvement in survival along 
with the complete protection of Salmonella 
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Bdellovibrio treated and control worms.  
One day after exposure to Bdellovibrio or 
a control buffer, E. coli K-12 levels were 
significantly lower in worms treated with 
Bdellovibrio compared to control worms 
(Fig. 3A).  Levels of pathogenic E. coli K-12 
decreased to undetectable levels in worms 
three days after Bdellovibrio treatment, while 
it took five days for pathogenic E. coli to drop 
below detectable levels in control worms.  
E. coli OP50 showed a similar trend in that 
bacterial levels were lower in Bdellovibrio 
treated worms, although a significant 
difference between Bdellovibrio treated and 
control worms was not detected until three 
days after Bdellovibrio treatment (Fig. 3B).  E. 
coli OP50 was also cleared to undetectable 
levels faster in Bdellovibrio treated worms 
and E. coli OP50, unlike E. coli K-12, persisted 
in the control worms for the entire seven 
day experiment.  The limit of pathogen 
detection was five CFU per five worms.  
treated worms clearly demonstrates the 
protective ability of Bdellovibrio in this 
system (Fig. 2 and Table 1).  The variation in 
Bdellovibrio protection of C. elegans from 
pathogens may be due to the difference 
in bacterial colonization of the worms.  S. 
enterica serovar Typhimurium kills worms 
through a persistent intestinal colonization 
while E. coli kills through a non-persistent 
intestinal colonization (16).  The ability of 
S. enterica to multiply within and distend 
the worm intestinal lumen, establishing a 
persistent infection after the worms are 
no longer being fed S. enterica cells (31), 
may provide a more concentrated source 
of pathogen cells to support increased 
Bdellovibrio growth and predation, leading 
to complete recovery from infection.  
Interestingly, these data suggest that the more 
numerous the pathogen cells are in the host, 
the more effective Bdellovibrio treatment 
may be for resolving the infection.  
We followed the persistence of two E. 
coli strains in this system using antibiotic-
resistant derivatives of E. coli K-12 and 
E. coli OP50 to examine the effect of 
Bdellovibrio on E. coli clearance from the 
worm.  Pathogenic E. coli K-12 levels were 
significantly lower in Bdellovibrio treated 
worms one day after treatment and E. coli 
K-12 was cleared from the worms two days 
quicker in Bdellovibrio treated worms (Fig. 
3A).  This marked reduction in pathogenic 
E. coli levels by Bdellovibrio was enough to 
significantly improve worm survival, but 
not enough to restore worm survival back 
to the level seen in non-pathogen treated 
control worms (Table 1).  Our results are 
based on a single, 15 minute exposure of 
the worms to Bdellovibrio and increased 
survival may occur with longer or repeated 
exposures of the worms to Bdellovibrio.  We 
chose a 15 minute exposure to allow time 
for Bdellovibrio to attach to prey cells and 
begin invasion of the prey cell (2).  Even 
without Bdellovibrio treatment, E. coli K-12 
was cleared from the worms, in agreement 
with earlier research demonstrating that 
pathogenic E. coli does not establish a 
persistent infection in worms (16).  Levels 
of nonpathogenic E. coli OP50 were also 
significantly lower and cleared faster 
in Bdellovibrio treated worms (Fig. 3B).  
However, unlike E. coli K-12, nonpathogenic 
E. coli OP50 was able to persist in the control 
worms for seven days.  The levels of E. coli 
OP50 we detected in control worms on day 
one agree closely with those found by others 
investigating viable E. coli OP50 counts in C. 
elegans lysates (30), validating our work in 
this system.        
C. elegans appears to be an ideal model 
system for refining and exploring the use 
of Bdellovibrio as a therapeutic agent.  Since 
C. elegans is a bacteriovore, exposure of 
the worms to pathogenic bacteria is simple 
and easy.  The lower growth temperatures 
favored by C. elegans (20-25°C) compared 
to birds and mammals coupled with 
Bdellovibrio’s optimal growth temperature of 
28°C makes C. elegans an attractive animal 
system to investigate the use of Bdellovibrio 
as a biocontrol agent.  We administered 
Bdellovibrio as a liquid treatment for precise, 
controlled dosing, but worms could also be 
treated with Bdellovibrio through placement 
on plaque plates (17) containing both the 
pathogen and Bdellovibrio.  Our work 
prepares the way for future experiments 
with C. elegans and Bdellovibrio to examine 
additional pathogens, dosage and frequency 
of Bdellovibrio treatment, persistence of 
Bdellovibrio in worms, effect (if any) of 
Bdellovibrio on worm morphology, as well as 
other variables.  
While an intriguing hypothesis, the use of 
Bdellovibrio as a feasible therapeutic agent has 
only been demonstrated in vivo in chickens 
against Salmonella (12).  Here we extend 
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